Bristol-Myers Squibb Videx
Executive Summary
Once-daily oral dose of two 200 mg didanosine chewable tablets approved by FDA Oct. 28. Videx' revised label also includes risk information about pancreatitis in patients receiving triple combination therapy including Videx, Bristol's Zerit (stavudine) and a protease inhibitor. Labeling has also added a precaution that "pancreatitis resulting in death was observed in one patient who received Videx plus stavudine plus nelfinavir [Warner-Lambert's Viracept]...and in one patient who received Videx plus stavudine plus indinavir [Merck's Crixivan]." Two of 68 patients receiving Videx/Zerit/Crixivan and Bristol's Droxil (hydroxyurea) died from pancreatitis, labeling continues
You may also be interested in...
Bristol Videx Once-Daily Dosing Restricted After Unfavorable Trial Results
Labeling for Bristol-Myers Squibb's Videx (didanosine) has been revised to recommend against once-daily dosing for most patients following negative findings from a clinical trial using the new 200 mg formulation of the drug.
Bristol Videx Once-Daily Dosing Restricted After Unfavorable Trial Results
Labeling for Bristol-Myers Squibb's Videx (didanosine) has been revised to recommend against once-daily dosing for most patients following negative findings from a clinical trial using the new 200 mg formulation of the drug.
Adefovir Expanded Access Enrollment Cited By Gilead To Support Approval
Gilead's adefovir dipivoxil is currently being used by physicians responsible for 70% of the prescriptions for AIDS antiretroviral therapies in the U.S., via the company's expanded access program.